Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Scotiabank Initiates Coverage On Tempest Therapeutics with Sector Outperform Rating, Announces Price Target of $13

Author: Benzinga Newsdesk | March 14, 2024 05:40am
Scotiabank analyst George Farmer initiates coverage on Tempest Therapeutics (NASDAQ:TPST) with a Sector Outperform rating and announces Price Target of $13.

Posted In: TPST

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist